{"title":"在美国继续与疫苗可预防的神经系统疾病作斗争。","authors":"Farrah J Mateen","doi":"10.1007/s13365-025-01256-9","DOIUrl":null,"url":null,"abstract":"<p><p>Few experts remain in the United States on the infectious vaccine-preventable neurological diseases (VPNDs). This is a mark of the changing epidemiology that has come with publicly available, often free, and sometimes mandated vaccinations in the U.S.A. over recent decades. Three main challenges to maintaining the battle against VPNDs exist in the U.S.A. today: (1) The variable uptake of vaccinations known to be safe and effective among the healthy U.S. population; (2) Waning awareness among physicians and community members on VPNDs; and (3) The global nature of travel, migration, medical tourism, and work. The mobility of the U.S. population and dependence on herd immunity in the USA for some residents may no longer be appropriate. This situation emphasizes the value of a global neurological disease framework for neurologists-in-training that could ultimately save lives in the USA. VPNDs must remain a part of the curriculum and board certification of both pediatric and adult neurologists in the USA given changes in U.S. policy and sentiment.</p>","PeriodicalId":16665,"journal":{"name":"Journal of NeuroVirology","volume":" ","pages":"187-190"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Maintaining the battle against vaccine-preventable neurological diseases in the United States.\",\"authors\":\"Farrah J Mateen\",\"doi\":\"10.1007/s13365-025-01256-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Few experts remain in the United States on the infectious vaccine-preventable neurological diseases (VPNDs). This is a mark of the changing epidemiology that has come with publicly available, often free, and sometimes mandated vaccinations in the U.S.A. over recent decades. Three main challenges to maintaining the battle against VPNDs exist in the U.S.A. today: (1) The variable uptake of vaccinations known to be safe and effective among the healthy U.S. population; (2) Waning awareness among physicians and community members on VPNDs; and (3) The global nature of travel, migration, medical tourism, and work. The mobility of the U.S. population and dependence on herd immunity in the USA for some residents may no longer be appropriate. This situation emphasizes the value of a global neurological disease framework for neurologists-in-training that could ultimately save lives in the USA. VPNDs must remain a part of the curriculum and board certification of both pediatric and adult neurologists in the USA given changes in U.S. policy and sentiment.</p>\",\"PeriodicalId\":16665,\"journal\":{\"name\":\"Journal of NeuroVirology\",\"volume\":\" \",\"pages\":\"187-190\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of NeuroVirology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13365-025-01256-9\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of NeuroVirology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13365-025-01256-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Maintaining the battle against vaccine-preventable neurological diseases in the United States.
Few experts remain in the United States on the infectious vaccine-preventable neurological diseases (VPNDs). This is a mark of the changing epidemiology that has come with publicly available, often free, and sometimes mandated vaccinations in the U.S.A. over recent decades. Three main challenges to maintaining the battle against VPNDs exist in the U.S.A. today: (1) The variable uptake of vaccinations known to be safe and effective among the healthy U.S. population; (2) Waning awareness among physicians and community members on VPNDs; and (3) The global nature of travel, migration, medical tourism, and work. The mobility of the U.S. population and dependence on herd immunity in the USA for some residents may no longer be appropriate. This situation emphasizes the value of a global neurological disease framework for neurologists-in-training that could ultimately save lives in the USA. VPNDs must remain a part of the curriculum and board certification of both pediatric and adult neurologists in the USA given changes in U.S. policy and sentiment.
期刊介绍:
The Journal of NeuroVirology (JNV) provides a unique platform for the publication of high-quality basic science and clinical studies on the molecular biology and pathogenesis of viral infections of the nervous system, and for reporting on the development of novel therapeutic strategies using neurotropic viral vectors. The Journal also emphasizes publication of non-viral infections that affect the central nervous system. The Journal publishes original research articles, reviews, case reports, coverage of various scientific meetings, along with supplements and special issues on selected subjects.
The Journal is currently accepting submissions of original work from the following basic and clinical research areas: Aging & Neurodegeneration, Apoptosis, CNS Signal Transduction, Emerging CNS Infections, Molecular Virology, Neural-Immune Interaction, Novel Diagnostics, Novel Therapeutics, Stem Cell Biology, Transmissable Encephalopathies/Prion, Vaccine Development, Viral Genomics, Viral Neurooncology, Viral Neurochemistry, Viral Neuroimmunology, Viral Neuropharmacology.